British pharmaceutical giant GSK on Monday said Chief Executive Emma Walmsley will step down after nearly nine years at the helm, to be replaced by its chief commercial officer.
Luke Miels will take over from Walmsley on January 1, 2026 GSK said in a statement.
The surprise announcement sent GSK shares up by over 3% in early trading, reflecting a positive reaction from investors who have long sought clearer direction and higher returns.
Earlier this month, GSK said it planned to invest $30 billion in the United States over the next five years, ahead of US President Donald Trump’s announcement last week that new tariffs will hit the pharmaceutical industry starting Wednesday.
Walmsley’s Legacy and Investor Pressure
Emma Walmsley, who took the helm in 2017, is credited with overseeing a significant strategic transformation of the company.
Her most notable move was the successful 2022 spin-off of the consumer healthcare division, Haleon (which owns brands like Sensodyne and Panadol), allowing the remaining core GSK business to focus squarely on specialty medicines and vaccines.
Despite these strategic successes, Walmsley’s tenure was marked by pressure from activist investors who cited a lackluster share price performance compared to rivals like AstraZeneca.
The stock’s jump following the news suggests the market is optimistic about the new leadership’s ability to accelerate growth.
Walmsley stated that 2026 “is a pivotal year for GSK to define its path for the decade ahead, and I believe the right moment for new leadership.” She will remain with the company in an advisory role through late 2026 to support the transition.
AFP